STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRMD
  4. [8-K] MARIMED INC. Reports Material Event

MariMed (MRMD) grows Q1 2026 sales, narrows loss and boosts EBITDA

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

MariMed Inc. reported first-quarter 2026 revenue of $39.5 million, up from $37.9 million a year earlier, driven by both retail and wholesale product sales. GAAP gross margin was 38.7%, with non-GAAP gross margin at 40.1%.

The company posted a GAAP net loss of $3.8 million, improving from a $5.5 million loss in 2025. Non-GAAP net loss was $3.2 million, while non-GAAP Adjusted EBITDA rose to $3.6 million and the Adjusted EBITDA margin increased to 9.1%.

MariMed highlighted a March 2 Restructuring and Exchange Agreement for $14.7 million of Series B convertible preferred stock, replacing a February 2026 mandatory conversion with longer-dated instruments and extending the weighted-average maturity to 4.6 years, which reduces near-term refinancing pressure and supports liquidity.

Positive

  • Improving profitability and cash generation: Q1 2026 GAAP net loss narrowed to $3.8 million from $5.5 million, non-GAAP Adjusted EBITDA increased to $3.6 million, and Adjusted EBITDA margin rose to 9.1%, while operating activities provided $0.9 million of cash.
  • Preferred stock restructuring reduces near-term risk: The March 2 Restructuring and Exchange Agreement for $14.725 million of Series B convertible preferred stock extended the weighted-average maturity of the obligation to 4.6 years, eliminating a February 26, 2026 mandatory conversion date and easing refinancing pressure.

Negative

  • Continued net losses and leverage: Despite progress, MariMed reported a Q1 2026 GAAP net loss of $3.8 million, an accumulated deficit of $131.7 million, and income taxes payable of $29.6 million, with total liabilities of $147.7 million as of March 31, 2026.

Insights

Q1 shows moderate growth, improving EBITDA, and lower near-term financing risk.

MariMed grew Q1 2026 revenue to $39.5 million from $37.9 million, with retail and wholesale both contributing. GAAP gross margin was 38.7%, while non-GAAP gross margin reached 40.1%, indicating stable unit economics despite industry pricing pressure.

Profitability trends improved: GAAP net loss narrowed to $3.8 million and non-GAAP Adjusted EBITDA increased to $3.6 million, lifting the Adjusted EBITDA margin to 9.1%. Cash from operations was $0.9 million in Q1 2026, showing the business is at least modestly cash-generative.

The March 2, 2026 restructuring of $14.725 million of Series B convertible preferred stock into longer-dated instruments extended the weighted-average maturity to 4.6 years. This removes a February 2026 mandatory conversion obligation and eases near-term refinancing risk, though total liabilities remain substantial with income taxes payable at $29.6 million as of March 31, 2026.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q1 2026 revenue $39.5M Three months ended March 31, 2026
Q1 2026 GAAP net loss $3.8M Three months ended March 31, 2026
Q1 2026 Non-GAAP Adjusted EBITDA $3.6M Three months ended March 31, 2026
Adjusted EBITDA margin 9.1% Three months ended March 31, 2026
Cash and equivalents $7.9M As of March 31, 2026
Income taxes payable $29.6M As of March 31, 2026
Total liabilities $147.7M As of March 31, 2026
Series B preferred restructured $14.725M Restructuring and Exchange Agreement, March 2, 2026
Non-GAAP Adjusted EBITDA financial
"The Company has provided in this release several non-GAAP financial measures: Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin"
Non-GAAP adjusted EBITDA is a measure of a company's profitability that shows earnings before interest, taxes, depreciation, and amortization, with certain adjustments made to exclude irregular or non-recurring expenses and income. It provides a clearer picture of ongoing operational performance by filtering out items that might distort the core business results. Investors use it to better compare how well different companies are performing without the noise of one-time events.
Series B convertible preferred stock financial
"Announced a Restructuring and Exchange Agreement with the holders of the $14.725 million Series B Convertible Preferred Stock."
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
Gain on extinguishment of debt financial
"Gain on extinguishment of debt | 699 | | | —"
Mezzanine equity financial
"Liabilities, mezzanine equity and stockholders’ equity"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
Weighted average common shares outstanding financial
"Weighted average common shares outstanding: | | | Basic | 397,450 |"
Weighted average common shares outstanding is the average number of a company’s common stock shares that were available during a reporting period, adjusted for share issuances, buybacks, splits or conversions that happened at different times. Investors use it to fairly calculate per‑share figures like earnings per share, because it’s like averaging how many cars were on a road over time rather than counting only a snapshot—giving a truer picture of value per share.
Revenue $39.5M
GAAP net loss $3.8M
Non-GAAP Adjusted EBITDA $3.6M
GAAP gross margin 38.7%
Non-GAAP gross margin 40.1%
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001522767FALSE00015227672026-05-132026-05-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2026
MARIMED INC.
(Exact name of registrant as specified in its charter)
Delaware0-5443327-4672745
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
10 Oceana Way
Norwood, MA 02062
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (781) 277-0007
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None.
Title of each classTicker symbol(s)Name of each exchange on which registered
Not Applicable.Not Applicable.Not Applicable.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02. Results of Operations and Financial Condition.
On May 13, 2026, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing its financial results for the three-month period ended March 31, 2026.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.		Description
99.1
Press release, dated May 13, 2026, announcing financial results for the three-month period ended March 31, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, furnished pursuant to Item 2.02, including Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
**********


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MARIMED INC.
Dated: May 13, 2026
By:/s/ Mario Pinho
Mario Pinho
Chief Financial Officer


Exhibit 99.1
picture2.jpg
MariMed Reports First Quarter 2026 Earnings

NORWOOD, MA, May 13, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2026.


Financial Highlights1
The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):
Three months ended
March 31,
2026
2025
(unaudited)
Revenue$39.5 $37.9 
GAAP Gross margin39%40%
Non-GAAP Gross margin40%41%
GAAP Net loss
$(3.8)$(5.5)
Non-GAAP Net loss
$(3.2)$(3.9)
Non-GAAP Adjusted EBITDA$3.6 $2.5 
Non-GAAP Adjusted EBITDA margin9%7%

1 See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” below and in the financials information included herewith.

Management Commentary

"The first quarter reflected MariMed's continued year-over-year growth, supported by expanded wholesale distribution, retail growth, and continued execution of our 'Expand the Brand' strategy of making our top-selling brands accessible to more people in both existing and new markets," said Jon Levine, MariMed's Chief Executive Officer.

"In an industry environment where many operators continue to face pricing compression and limited growth, MariMed continues to strengthen profitability, expand branded distribution, and reinforce the market positioning of our core brands through disciplined operational execution," he continued.

"Our products maintained or grew their market-leading positions in the most popular categories across our wholesale markets, demonstrating our operational excellence across innovation, manufacturing, and sell-through. Following the recent historic rescheduling announcement and


continued progress of our 2026 growth drivers, MariMed is well-positioned to capitalize on this transformative period for our industry."

"We also remain focused on disciplined capital execution, operational efficiency, and strengthening liquidity while continuing to invest in high-return growth opportunities that support long-term shareholder value creation."

Conference Call

MariMed management will host a conference call on Thursday, May 14, 2026 at 8:00 a.m. Eastern time, to discuss these results. The conference call may be accessed through MariMed’s Investor Relations website, or by clicking the following link: Q126 MRMD Earnings Call.
First Quarter 2026 Operational Highlight
During the first quarter, the Company announced the following development in the implementation of its strategic growth plan:

•March 2: Announced a Restructuring and Exchange Agreement with the holders of the $14.725 million Series B Convertible Preferred Stock. The Agreement eliminated the Company's February 26, 2026 mandatory conversion date obligation and replaced it with a combination of long-dated instruments. The transaction extends the weighted average maturity of the obligation to 4.6 years, eliminating near-term refinancing risk and enhancing the Company's liquidity profile.
Discussion of Non-GAAP Financial Measures

MariMed’s management uses several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, making operating decisions, and planning and forecasting future periods. The Company has provided in this release several non-GAAP financial measures: Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, Non-GAAP Gross margin, Non-GAAP Operating expenses and Non-GAAP Net income (loss), as supplements to Revenue, Gross margin, Operating expenses, Income (loss) from operations, Net income (loss) and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, and when planning and forecasting future periods, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP financial measures, the Company’s calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.



Management defines non-GAAP Adjusted EBITDA as income (loss) from operations, determined in accordance with GAAP, excluding the following items:

•depreciation and amortization of property and equipment;
•amortization of acquired intangible assets;
•impairment or write-downs of acquired intangible assets;
•inventory revaluation;
•stock-based compensation;
•severance;
•legal settlements; and
•acquisition-related and other expenses.

For further information, please refer to the publicly available financial filings available on MariMed's Investor Relations website, as filed with the U.S. Securities and Exchange Commission, or as filed with the Canadian securities regulatory authorities on the SEDAR website.

About MariMed

MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Important Caution Regarding Forward-Looking Statements

The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2026, including anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements. Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and


other factors can be found in our reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.
For More Information Contact:
Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

# # #


MariMed Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

March 31,
2026		December 31,
2025
Assets  
Current assets:  
Cash, cash equivalents and restricted cash$7,937 $8,884 
Accounts receivable, net9,439 9,114 
Inventory39,296 36,601 
Notes receivable, current portion866 866 
Other current assets3,250 3,825 
Total current assets60,788 59,290 
Property and equipment, net88,054 89,385 
Intangible assets, net16,400 17,210 
Goodwill24,002 24,002 
Operating lease right-of-use assets7,539 7,723 
Finance lease right-of-use assets3,452 4,024 
Other assets950 931 
Total assets$201,185 $202,565 
   
Liabilities, mezzanine equity and stockholders’ equity
Current liabilities:
Mortgages and notes payable, current portion$3,295 $2,553 
Accounts payable15,109 14,586 
Accrued expenses and other10,357 9,509 
Deferred revenue1,473 1,394 
Income taxes payable29,589 26,981 
Operating lease liabilities, current portion1,998 1,952 
Finance lease liabilities, current portion1,938 2,092 
Total current liabilities63,759 59,067 
Mortgages and notes payable, net of current portion76,027 70,192 
Operating lease liabilities, net of current portion6,387 6,616 
Finance lease liabilities, net of current portion1,566 1,956 
Total liabilities147,739 137,831 
  
Commitments and contingencies
  
Mezzanine equity  
Series B convertible preferred stock— 14,725 
New Series B convertible preferred stock
6,933 — 
Total mezzanine equity6,933 14,725 
  
Stockholders’ equity  
Common stock399 397 
Additional paid-in capital179,723 179,405 
Accumulated deficit(131,717)(127,932)
Noncontrolling interests(1,892)(1,861)
Total stockholders’ equity46,513 50,009 
Total liabilities, mezzanine equity and stockholders’ equity$201,185 $202,565 


MariMed Inc.
Condensed Consolidated Statements of Operations
(in thousands, except percentages and per share amounts)
(unaudited)

Three months ended
March 31,
20262025
Revenue$39,481 $37,906 
Cost of revenue24,205 22,817 
Gross profit15,276 15,089 
   
Gross margin38.7%39.8%
Operating expenses:
Personnel7,254 7,341 
Marketing and promotion765 908 
General and administrative6,887 6,250 
Acquisition-related and other169 112 
Bad debt76 1,388 
Total operating expenses15,151 15,999 
Income (loss) from operations125 (910)
Interest and other (expense) income:
Interest expense(1,976)(1,762)
Interest income36 24 
Gain on extinguishment of debt699 — 
Total interest and other expense, net(1,241)(1,738)
Loss before income taxes(1,116)(2,648)
Provision for income taxes2,651 2,831 
Net loss(3,767)(5,479)
Less: Net income attributable to noncontrolling interests18 32 
Net loss attributable to common stockholders$(3,785)$(5,511)
Net loss per share attributable to common stockholders:
Basic$(0.01)$(0.01)
Diluted$(0.01)$(0.01)
Weighted average common shares outstanding:  
Basic397,450 382,557 
Diluted397,450 382,557 


MariMed Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

Three months ended
March 31,
20262025
Cash flows from operating activities:
Net loss attributable to common stockholders$(3,785)$(5,511)
Net income attributable to noncontrolling interests18 32 
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation and amortization of property and equipment2,153 1,807 
Amortization of intangible assets810 949 
Stock-based compensation325 547 
Amortization of debt discount115 105 
Amortization of debt issuance costs18 18 
Payment-in-kind interest— 30 
Bad debt expense76 1,388 
Obligations settled with common stock— 1 
Loss on disposal of assets— 111 
Gain on extinguishment of debt(699)— 
Changes in operating assets and liabilities:
Accounts receivable, net(401)(303)
Deferred rents receivable— 12 
Inventory(2,695)(453)
Other current assets999 240 
Other assets(19)(2,542)
Accounts payable523 86 
Accrued expenses and other829 1,888 
Deferred revenue74 59 
Income taxes payable2,608 2,829 
Net cash provided by operating activities949 1,293 
  
Cash flows from investing activities:
Purchases of property and equipment(373)(266)
Business combinations, net of cash acquired, and asset purchases— 231 
Advances toward future business combinations and asset purchases— (50)
Purchases and renewals of cannabis licenses(380)(56)
Proceeds from notes receivable— 26 
Net cash used in investing activities(753)(115)
   


Three months ended
March 31,
20262025
Cash flows from financing activities:
Principal payments of mortgages(414)(401)
Principal payments of promissory notes(236)(478)
Principal payments of finance leases(444)(322)
Distributions(49)(58)
Net cash used in financing activities(1,143)(1,259)
  
Net decrease in cash and cash equivalents(947)(81)
Cash and equivalents, beginning of year8,884 7,201 
Cash and cash equivalents, end of period$7,937 $7,120 


MariMed Inc.
Reconciliation of Non-GAAP and GAAP Financial Measures
(in thousands, except percentages)
(unaudited)


 Three months ended
March 31,
 20262025
Non-GAAP Adjusted EBITDA
GAAP Income (loss) from operations$125 $(910)
Depreciation and amortization of property and equipment2,153 1,807 
Amortization of acquired intangible assets810 949 
Stock-based compensation325 547 
Acquisition-related and other169 112 
Adjusted EBITDA$3,582 $2,505 
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)
GAAP Income from operations0.3%(2.4%)
Depreciation and amortization of property and equipment5.5%4.8%
Amortization of acquired intangible assets2.1%2.5%
Stock-based compensation0.8%1.4%
Acquisition-related and other0.4%0.3%
Adjusted EBITDA margin9.1%6.6%
GAAP Gross margin38.7 %39.8 %
Amortization of acquired intangible assets1.4 %1.4 %
Non-GAAP Gross margin40.1 %41.2 %

GAAP Operating expenses$15,151 $15,999 
Amortization of acquired intangible assets(263)(411)
Stock-based compensation(325)(547)
Acquisition-related and other(169)(112)
Non-GAAP Operating expenses$14,394 $14,929 

GAAP Net loss$(3,767)$(5,479)
Amortization of acquired intangible assets810 949 
Stock-based compensation325 547 
Acquisition-related and other169 112 
Gain on extinguishment of debt(699)— 
Non-GAAP net loss$(3,162)$(3,871)



MariMed Inc.
Supplemental Information
Revenue Components
(in thousands)
(unaudited)

Three months ended
March 31,
20262025
Product sales - retail$21,727 $20,730 
Product sales - wholesale17,517 16,786 
Other revenue237 390 
  Total revenue$39,481 $37,906 

Source: View Original Filing on SEC EDGAR

FAQ

How did MariMed (MRMD) perform financially in Q1 2026?

MariMed generated $39.5 million in Q1 2026 revenue, up from $37.9 million a year earlier. GAAP net loss improved to $3.8 million from $5.5 million, while non-GAAP Adjusted EBITDA rose to $3.6 million, reflecting better operating performance and margin expansion.

What were MariMed (MRMD)’s profit margins in the first quarter of 2026?

MariMed reported a GAAP gross margin of 38.7% and a non-GAAP gross margin of 40.1% in Q1 2026. The non-GAAP Adjusted EBITDA margin reached 9.1%, up from 6.6% in 2025, indicating improved efficiency after excluding non-cash and non-operating items.

How large was MariMed (MRMD)’s net loss in Q1 2026?

MariMed’s GAAP net loss for Q1 2026 was $3.8 million, compared with a $5.5 million loss in Q1 2025. On a non-GAAP basis, net loss was $3.2 million versus $3.9 million, showing gradual progress toward profitability while still operating at a loss.

What did MariMed (MRMD) disclose about its Series B convertible preferred stock?

On March 2, 2026, MariMed announced a Restructuring and Exchange Agreement covering $14.725 million of Series B convertible preferred stock. The deal removed a February 26, 2026 mandatory conversion and replaced it with longer-dated instruments, extending weighted-average maturity to 4.6 years and easing near-term refinancing risk.

How much cash and debt did MariMed (MRMD) report as of March 31, 2026?

As of March 31, 2026, MariMed had $7.9 million in cash, cash equivalents, and restricted cash. Total mortgages and notes payable were $79.3 million combined current and long-term, contributing to total liabilities of $147.7 million on total assets of $201.2 million.

What were MariMed (MRMD)’s main revenue drivers in Q1 2026?

In Q1 2026, MariMed’s revenue totaled $39.5 million, primarily from cannabis product sales. Retail product sales were $21.7 million, wholesale product sales were $17.5 million, and other revenue contributed $0.2 million, reflecting the company’s focus on branded retail and wholesale distribution.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents